Vernalis and GlaxoSmithKline (GSK) sign a risk-sharing agreement to develop oncology drug candidates for an undisclosed cancer target. Vernalis is responsible for the discovery work while GSK takes on the preclinical development with an option to license and develop further. The deal will help Vernalis to boost its financial situation following its setback with frovatriptan.